SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023)

SAB Biotherapeutics (SABS) has 3 years of Change in Receivables data on file, last reported at -$361735.0 in Q3 2023.

• Quarterly Change in Receivables fell 110.86% year-over-year to -$361735.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$5.6 million (down 126.42% YoY) and the FY2023 annual result came in at -$5.6 million, down 126.42% from the prior year.
• Change in Receivables rose to -$361735.0 in Q3 2023, from -$401388.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $5.5 million in Q2 2021 to a low of -$9.0 million in Q1 2021.
• A 3-year average of -$1.9 million and a median of -$2.2 million in 2022 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 148.28% in 2022, down 235.32% in 2022.
• Tracing SABS's Change in Receivables over 3 years: stood at -$2.2 million in 2021, then plunged by 235.32% to -$7.4 million in 2022, then surged by 95.1% to -$361735.0 in 2023.
• The last three Change in Receivables figures came in at -$361735.0 (Q3 2023), -$401388.0 (Q2 2023), and -$4.8 million (Q1 2023), per Business Quant data.